TEXTBOOK OF HEMOPHILIA

Part I: Introduction
1 Overview of hemostasis
2 Cellular processing of factor VIII and factor IX

Part II: Hemophilia A
3 Molecular basis of hemophilia A
4 Prophylaxis

Part III: Inhibitors to factor VIII
5 Inhibitors to factor VIII: immunology
6 Genetic and environmental risk factors for FVIII inhibitor development
7 Epidemiology of inhibitors in hemophilia
8 Inhibitors to factor VIII: mild and moderate hemophilia
9 Inhibitors to factor VIII/IX: immune tolerance
10 Prophylaxis in inhibitor patients
11 Inhibitors to factor VIII: treatment of acute bleeds

Part IV: Acquired hemophilia
12 Acquired inhibitors to Factor VIII

Part V: Hemophilia B
13 Hemophilia B: molecular basis
14 Factor IX inhibitors in hemophilia B
15 Treatment of inhibitors in hemophilia B

Part VI: Pharmacokinetics of factors VIII & IX
16 Pharmacokinetics
17 Individualised dosing

Part VII: Hemophilia - birth to old age
18 The neonate with hemophilia
19 Work-up of a bleeding child
20 Care of the child with hemophilia
21 Adolescence
22 Old age medicine and hemophilia

Part VIII: Products used to treat hemophilia
23 Products used to treat hemophilia: recombinant products
24 Products used to treat hemophilia: plasma-derived coagulation factor concentrates
25 Products used to treat hemophilia: dosing
26 Products used to treat hemophilia: regulation
27 New drugs in the pipeline: From concept to clinic

Part IX: Surgical management
28 General surgical management of patients with hemophilia
29 Continuous infusion of coagulation products in hemophilia
30 Surgery in inhibitor patients

Part X: Musculoskeletal
31 Joint replacement
32 Medical synovectomy (synoviorthesis) in hemophilia: Radiosynovectomy and chemical synovectomy
33 Pseudotumors in patients with hemophilia
34 Imaging modalities for assessment of hemophilic arthropathy
35 Physiotherapy in the management of hemophilia
36 Outcome assessment in hemophilia

Part XI: Transfusion-transmitted Disease
37 Viral hepatitis and hemophilia
38 Transfusion-transmitted disease: Emerging infections
39 vCJD and hemophilia

Part XII: Gene therapy
40 Hemophilia gene therapy: an overview
41 Gene therapy trials in hemophilia A and B
42 Gene therapy: molecular engineering of factor VIII and Factor IX

Part XIII: Laboratory
43 Laboratory and quality control of assays
44 Standardization of assays in hemophilia
45 Global laboratory assays in hemophilia

Part XIV: Women and bleeding disorders
46 Obstetrics and gynecology: hemophilia
47 Women and von Willebrand disease

Part XV: von Willebrand disease
48 von Willebrand disease: molecular aspects
49 von Willebrand disease: epidemiology
50 von Willebrand disease: biological diagnosis
51 Classification and clinical aspects of von Willebrand disease
52 Treatment of von Willebrand disease: desmopression
53 Treatment of von Willebrand disease: therapeutic concentrates

Part XVI: Rare bleeding disorders
54 Factor II
55 Factor V and combined Factor V and VIII deficiencies
56 Congenital factor VII deficiency
57 Factor X and Factor X Deficiency
58 Factor XI deficiency
59 Factor XIII deficiency
60 Fibrinogen deficiency
61 Miscellaneous rare bleeding disorders

Part XVII: Emergency medicine
62 Emergency medicine and inherited blood disorders

Part XVIII: Evaluation of hemophilia
63 Clinical trials and other methodologies
64 Quality of life in hemophilia
65 The economics of hemophilia treatments

Part XIX: Comprehensive care and delivery of care
66 Hemophilia databases
67 Comprehensive care and the delivery of care: the developed world
68 Comprehensive care and delivery of care in hemophilia: the developing world
69 Comprehensive care and delivery of care: the global perspective

Without doubt, Textbook of Hemophilia, 3rd edition is the definitive reference source on all aspects of haemophilia including diagnosis, management and treatment. Edited by three, world-renowned experts on haemophilia, this completely revised resource features chapters written by over 60 international contributors with international expertise in caring for haemophilia patients.

- Features eight new chapters, covering individualised dosing, vCJD and haemophilia, new drugs in the pipeline, and surgery in inhibitor patients
- Presents new developments, such as gene therapy
- Highlights controversial issues and provides advice for everyday clinical questions
- Represents essential reading for all healthcare professionals involved in the care of those with haemophilia

Author Information
- Christine A. Lee, MA, MD, DSc, FRCP, FRCPath, FRCOG. Emeritus Professor of Haemophilia, University of London, London, UK
- Erik E. Berntorp, MD, PhD. Professor of Coagulation Medicine, Lund University. Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden.
- W. Keith Hoots, MD. Director, Division of Blood Diseases and Resources. National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD; Professor of Pediatrics and Internal Medicine, University of Texas Medical School at Houston, Houston, TX, USA.